Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and autoimmune diseases, has reported positive outcomes from a Phase II clinical trial for its tyrosine kinase 2 (TYK2) inhibitor, ICP-332. The randomized, double-blind, placebo-controlled study is investigating the efficacy of ICP-332 in patients with moderate to severe atopic dermatitis (AD).
ICP-332, classified as a Category 1 innovative drug, is proprietary to InnoCare with intellectual property protection. TYK2, a non-receptor tyrosine kinase within the Janus kinase (JAK) family, is a crucial enzyme in the JAK-STAT signaling pathway, playing a significant role in T cell inflammation pathogenesis. ICP-332 is designed to efficiently and selectively inhibit TYK2, thereby mitigating inflammation and anemia associated with adverse drug reactions.
The Phase II study demonstrated ICP-332’s excellent efficacy and safety profile in patients following four weeks of treatment, achieving multiple efficacy endpoints in both the 80mg and 120mg dosage groups. These endpoints included EASI (Eczema Area and Severity Index) 50, EASI 75, and EASI 90 (indicating a minimum 50%, 75%, and 90% improvement from baseline EASI score), and Investigator Global Assessment (IGA) 0/1 (complete or near-complete clearance of lesions).- Flcube.com
